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For the first time, the characterization of intact 150-kDa monoclonal antibodies (MAbs) using
a commercially available three-dimensional ion-trap mass spectrometer (IT-MS) is reported.
The IT-MS analysis was performed on-line with reversed-phase high performance liquid
chromatography (RP-HPLC) on a POROS column using a nontraditional solvent system of
acetonitrile, isopropanol, ethanol, and water in formic acid. The operating parameters of the
IT-MS were optimized by extending the mass range to m/z 4000 and elevating the tube lens
offset voltage value to around 100 V. Mass accuracy better than 300 ppm (40 Da) has been
routinely achieved for these macromolecules. Multiple peaks 162 Da apart due to the hexose
variants of the monoclonal IgG antibodies were partially resolved in mass spectra. Several
commercial and chimeric antibodies have been investigated in this study. (J Am Soc Mass
Spectrom 2005, 16, 307–311) © 2004 American Society for Mass SpectrometryThe human monoclonal immunoglobulin  (IgG)molecule is the most popular modality in themodern protein pharmaceutics because of its
controlled functions, predictable physiochemical prop-
erties, and long life in circulation [1]. Monoclonal anti-
bodies (MAbs) have been successfully commercialized
in the biotechnology field for the past ten years. These
products have emerged as primary protein therapeutic
research and development platforms. Although anti-
bodies have structural similarities, their post-transla-
tional modifications on heavy and light chains require
constant monitoring from cell culture to final formu-
lated products. Thus, it is obvious that the analysis of
intact therapeutic monoclonal antibodies by reversed-
phase (RP) high-performance liquid chromatography
(HPLC) online with mass spectrometry (LC/MS) would
dramatically reduce sample preparation and data inter-
pretation and also minimizes putative modifications
that may occur during sample preparation, such as
during peptide mapping experiments after enzymatic
digestion [2].
In recent years, electrospray mass spectrometry (ESI-
MS) [3], techniques to obtain maximum sample transfer
efficiency [4, 5] and combination of ionization modes
and mass analyzers [6] have enhanced the ability to
characterize small to medium sized proteins (100
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laser desorption/ionization time-of-flight (MALDI-
TOF) [7, 8], ESI orthogonal-TOF [9, 10] and ESI quad-
rupole [2, 11–13] mass spectrometers have been the
instruments of choice for MAbs and macromolecules,
largely due to the large m/z range of the TOF and high
ion transmission efficiency of the quadrupole mass
analyzers. Unfortunately, on-line RP-HPLC has not
accompanied these previous studies of intact monoclo-
nal antibodies.
Reversed-phase liquid chromatography is an impor-
tant component of intact protein analysis because it has
the ability to separate species based on minor structural
heterogeneity and, coupled to standard HPLC detec-
tors, provides quantitative information about the main
component, variants, and cleavage products. Because of
the large size and hydrophobic nature of antibodies,
employment of reversed phase liquid chromatography
on-line with mass spectrometry for the analysis of intact
antibodies has recently been developed in our labora-
tories [14 –16]. Until recently, perfusion chromatogra-
phy utilizing highly cross linked polystyrene-devinyl-
benzene (POROS) resins has often been used for
separation and purification of antibodies [17, 18]. This
technique suffers from limited separation efficiency
attributable to high flow rates of 0.5–3.0 mL/min re-
quired for separation and signal suppression due to
trifluoroacetic acid (TFA)-containing mobile phases
(acetonitril/water/TFA) which is not the most popular
solvent for electrospray ionization of proteins [19].
Thus, an alternate combination of mobile phase consist-
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Solvent B for RP LC/MS analysis of glycosylated pep-
tides [20].
Since the invention [21] and pioneering works of
Wolfgang Paul on the three-dimensional quadrupole
ion-trap (QIT) [22], numerous landmark research pa-
pers have described interesting modes of operation and
demonstrated a variety of specific applications [23–26]
that illustrate the usefulness of this nascent type of mass
spectrometry, especially for small molecules and pep-
tides. Unfortunately, without RP-HPLC, the analysis of
intact antibody [27] has required a tedious combination
of analytical techniques and extensive modifications of
the ion trap analyzer. The main reasons for the lack of
published material is thought to be attributable first, to
the well recognized limitations of the ion-trap mass
spectrometers to detect highly charged ions of MAbs
due to the space charge issues [28], and second, several
suitable solvent systems and optimal ionization volt-
ages must be determined to deliver intact antibodies
and to initiate the ionization process in the ion source
region (spray needle [“nozzle”]/skimmer) of an ion-
trap mass spectrometer, respectively. This is the first
report about analysis of intact monoclonal antibodies
by electrospray ionization on a commercial three-di-
mensional quadrupole ion trap mass spectrometer cou-
pled with RP-HPLC (IT-LC/MS). This innovative tech-
nique was achieved by interfacing a POROS column
that is operated in reversed-phase mode using nontra-
ditional solvents of acetonitrile, isopropanol, ethanol
and water in formic acid (FA). The RP-HPLC system
first allowed us to obtain acceptable chromatographic
resolution of intact antibodies and their degradation
products or clip forms. More importantly, molecular
masses of the intact antibodies were obtained with
unprecedented accuracy by optimizing the tube lens
offset voltages and automatic gain control (AGC) to
obtain maximum sample transfer efficiency while per-
haps minimizing space charging effects.
Experimental
A commercial IgG1 antibody Herceptin (calculated MW
 148,058 Da, Genentech, San Francisco, CA) [29] and a
chimeric IgG2 antibody produced at Amgen (calculated
MW  147,353 Da, Amgen Inc., Thousand Oaks, CA)
were used in this study. The IgG2 antibody was sub-
jected to an accelerated stability study under elevated
temperatures, which caused degradations of the mole-
cule. The HPLC system consisted of a HP-1100 (Agilent,
Palo Alto, CA) equipped with a heated 75 °C POROS
R1/10 1-1014-24 (Applied Biosystems, Framingham,
MASS) analytical column (4.6 mm  50 mm) and
operated at a flow rate of 450 L/min. The RP-HPLC
system was connected on-line to a Thermo Finnigan
LCQ DECA ion trap spectrometer equipped with an
off-axis electrospray ionization (ESI) source. Ten g
aliquots of the antibodies were injected per analysis.
The IgG1 antibody, Herceptin, was evaluated by IT-LC/MS utilizing an elution composition of 0.08% aque-
ous FA (Solvent A) with a linear gradient of acetoni-
trile/ethanol (8:2 vol/vol) in 0.08% FA (Solvent B).
After a 3 min isocratic hold, a linear gradient started at
20% B and increased to 55% B in 12 min (2.92% B/min)
followed by an isocratic hold for 3 min. The column was
then further washed to 98% B in an additional 12 min
(3.58% B/min) of a 30 min gradient. This solvent/
gradient system is referred here as ACN/ETOH con-
taining. It is noticed that IgG1 fractionate differently
than IgG2 antibody with this solvent/gradient system.
To effect acceptable resolution and separation of IgG2
antibody preparation, our laboratory evaluated many
mobile phase solvent systems. One of the better mobile
phase solvent systems for an IgG2 chimeric antibody was
ACN/IPA/ETOH/WA, which was composed of the fol-
lowing: 0.08% aqueous FA (Solvent A) and acetonitrile/
isopropanol/ethanol/water (6.0:1.5:1.5:1.0 vol/vol/vol/
vol) in 0.08% FA (Solvent B). Following an isocratic
post-injection hold, 5 min, the linear gradient started at
25% B was increased to 60% B within 15 min and held for
5 min. The column was then washed to 98% B (2.53%
B/min) for the next 15 min of a 40 min gradient. Depend-
ing upon the types of antibodies and their specific formu-
lation buffers, the column wash cycle could take 30 min.
The ion trap LCQ Deca mass spectrometer was
operated under Xcalibur 1.2 software (Thermo Finni-
gan, San Jose, CA). The mass range of 1200–3800 m/z
was calibrated in the positive ion mode with multiple-
ion monitoring of four ions signals of [M 7H]7 m/z
1730.0, [M  6H]6  m/z 2018.5, [M  5H]5  m/z
2421.8, [M  4H]4  m/z 3026.0 of a truncated form
(MW: 12,103 Da) of a sTNF-R1 protein [30] for this
study instead of polypropylene glycol (PPG). Mass
spectra of both IgG1- and IgG2 antibody analyses were
acquired over a range from m/z 2100–3800. The mass
spectrometric acquisition required the tube lens offset
voltage was set at 100 V (25 V). The voltage of the
ion-spray needle was 5000 V (200 V) and the temper-
ature of the heated capillary was 280 (20 °C). The
AGC setting of full mass was occasionally changed to 5
 E8 from conventional setting of 5  E7. Other targets
and duration of micro-scan were approximately at their
default values.
Results and Discussion
Since the amino acid sequences of antibodies used in
this report are known, the purpose of this study was to
confirm unambiguously the molecular weight of these
antibodies by IT- LC/MS. Figure 1a shows an
HPLC-UV chromatogram of the IgG1 (Herceptin) anti-
body after separation on POROS column. Figure 1b is a
positive ion ESI mass spectrum of the main chromato-
graphic peak acquired in the range from m/z 2400–3500
and featuring multiply charged ions from 44 to 60.
Figure 1c shows the convoluted and deconvoluted ESI
mass spectrum of IgG1 antibody with resolving masses
148,098 and 148,260 Da. The difference in mass of 162
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Figure 1. (a) A RP-HPLC chromatogram of an IgG1 antibody
used in this study with UV detection at 215 nm. Inset shows a
generic schematic of IgG1 antibody. (b) An expended positive ESI
mass spectrum of intact IgG1 antibody Herceptin from m/z 2400–
3500 with charged ions ranging from 43 to 61. The spectrum
was reconstructed by removing excessive noise signals and arti-
facts caused by the application software. (c) The corresponding
convoluted and deconvoluted mass spectra (reconstructed) of
Herceptin antibody and its associated structural micro-heteroge-
neity: 148,098 Da and 148,260 Da, respectively. The observed mass
difference of 162 Da is correlated with a loss of a hexose residue
(Hex, 162 Da), which is a typical heterogeneity of glycosylation
observed in IgG antibodies produced in mammalian cells.served in IgG antibodies produced in mammalian cells[13]. When the same ACN/ethanol containing mobile
phase was used for IgG2 antibody, chromatographic
resolution efficiency was significantly reduced (data are
not shown). To improve eluotropic properties of the
mobile phase and obtain better separation of the deg-
radation products of IgG2 antibody, iso-propanol was
added to Solvent B. Thus, depending upon the subclass
of antibody being examined, IgG1 or IgG2, it would be
important to optimize the chromatographic mobile
phase to effect maximal resolution. Figures 1a and 2a
illustrated the need to have a different mobile phase
system to obtain better chromatographic resolution for
IgG2 antibodies compared to an IgG1.
Figure 2a shows an HPLC UV chromatogram of the
IgG2 antibody. On the chromatogram, the low MW
cleavage products of 12 to 24 kDa (clips) eluting from
9.5 to 9.8 min were chromatographically separated from
the high MW components of the degraded IgG2 sample.
Because of the limited resolution of the chromato-
graphic peaks eluting from 10.3 to 11.5 min, we were
not able to accurately measure the masses of degrada-
Figure 2. (a) A RP-HPLC chromatogram of an IgG2 antibody
used in this study after separation on POROS column with UV
detection at 215 nm. The observed multiple degradation products
were induced by storage at elevated temperatures over an ex-
tended period of time. (b) The corresponding positive ESI mass
spectrum of the chromatographic peaks eluting from 11.3 to 13.5
min in (a) featuring multiply charged ions from 44 to 63. The
deconvoluted mass spectrum of the observed mass of 147,348 Da
of this IgG2 antibody is closely matched its theoretical mass of
147,353 Da.
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a positive ion ESI mass spectrum of the chromato-
graphic peaks eluting from 10.3 to 13.5 min acquired in
the range from m/z 2200–3400 and featuring multiply
charged ions from 44 to 63. Figure 2c shows the
deconvoluted ESI mass spectrum of IgG2 antibody in
the mass range of the intact molecule with measured
mass of 147,348 Da. The glycosylation profile featuring
different number of hexoses was not resolved in this
case. The measured mass agreed well with the calcu-
lated MW  147,353 Da for glycosylation structure
without any terminal hexose residues [13]. These results
have been confirmed by size exclusion chromatography
and MALDI-TOF analyses in our laboratory (data are
not shown). The control experiments confirmed that the
degradations products of the IgG2 antibody were in-
deed caused by the storage conditions and not by the
low pH, elevated temperature environment on the
POROS column. It was also observed that the multiple
chromatographic peaks eluting from 10.3 to 13.5 min
were either obscured or totally hidden when using the
mobile phase containing only ACN/ethanol/water/FA
combination of solvents. The addition of iso-propanol
to our perfusion chromatography system improved
separation and elution properties similar to our labora-
tory experiments on silica based C8 stationary phases
[15]. In this report, the mass accuracy was measured
and averaged after three consecutive LC/MS runs for
each antibody and it was determined within 300 ppm
for IgG1 antibody and 100 ppm for IgG2 antibody.
Our experiments focused on optimization of the
IT-LC/MS show that the ion transfer efficiency from
atmosphere to the ion trap could be greatly improved
by increasing amplitude of the tube lens offset voltages.
The tube lens voltage provides the potential voltage
drop to accelerate the highly charged ions during the
ionization spray processes by confining and focusing
them at the entrance of the ion-trap skimmer after they
exist the heated capillary [31]. In this region, the elec-
trospray particles move with the velocity of sound
(300 m/s) as a result of the free jet expansion into the
vacuum. For the 150-kDa ions of antibody, this velocity
corresponds to a relatively high kinetic energy of 60
eV. It required a larger focusing potential (100 V)
provided by the tube lens to focus the ions into the
orifice of the skimmer. In addition, we believe that
another factor to consider is the dissociation of ion in
the nozzle/skimmer region, as was pointed out by
Rockwood and co-workers [32]. It is easier to dissociate
highly charged ions by acceleration in the nozzle/
skimmer because of at least two factors. First, because
they are more highly charged, they acquire more kinetic
energy by being accelerated. Second, highly charged
ions tend to be inherently less stable because Coulombic
repulsion destabilizes them, making it easier to break
ions into fragments. Therefore, if the potential voltage
drop is set too high, loss of ions will occur because they
will dissociate, especially for highly charged ions. Thus,
the voltage drop potential in the nozzle/skimmer needsto be high enough to desolvate intact antibody ions, but
not so high as to dissociate them.
Conclusions
We have demonstrated, for the first time, that intact
150-kDa monoclonal antibodies and their potential deg-
radation products could be characterized by electro-
spray ionization using a standard commercial three-
dimensional ion-trap mass spectrometer coupled on-
line with RP-HPLC (IT-LC/MS). To the best of our
knowledge, these 150-kDa antibodies are the largest
proteins detected by an unmodified ion-trap mass spec-
trometer thus far. In this report, we focused our appli-
cations on a POROS analytical column to accomplish
our objectives of determining molecular masses of an-
tibodies. A combination of employing the nontradi-
tional solvent systems and optimizing the transfer effi-
ciency of the sample by lowering the tube lens offset
voltages of the QIT led to the successful development of
this “Trap for MAbs” method. We anticipate that the
chromatographic peak resolutions as well as the sensi-
tivity of the mass spectrometer can be substantially
improved with either narrow bore POROS columns or
other commercially available columns or other solvent
systems. The analysis of intact antibodies in protein
pharmaceutics opens a new field of applications for
three dimensional ion trap mass spectrometry, which,
until recently, has been considered as mainly a tool for
peptide mapping of proteins after their enzymatic di-
gestion.
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